(Q36615576)

15 August 2017

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease (English)

1 reference

15 August 2017

1 reference

2

Sophie Paczesny

1 reference

15 August 2017

John E Levine

1

1 reference

15 August 2017

Shin Mineishi

3

1 reference

15 August 2017

Thomas Braun

4

1 reference

15 August 2017

Sung W Choi

5

1 reference

15 August 2017

Raymond J Hutchinson

6

1 reference

15 August 2017

Dawn Jones

7

1 reference

15 August 2017

Yasser Khaled

8

1 reference

15 August 2017

Carrie L Kitko

9

1 reference

15 August 2017

Daniel Bickley

10

1 reference

15 August 2017

Oleg Krijanovski

11

1 reference

15 August 2017

Pavan Reddy

12

1 reference

15 August 2017

Gregory Yanik

13

1 reference

15 August 2017

James L M Ferrara

14

1 reference

15 August 2017

language of work or name

English

0 references

publication date

27 November 2007

1 reference

15 August 2017

1 reference

15 August 2017

111

1 reference

15 August 2017

4

1 reference

15 August 2017

2470-2475

1 reference

Etanercept: a review of its use in the management of rheumatoid arthritis

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Prophylaxis and treatment of acute graft-versus-host disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Diverse effects of infliximab and etanercept on T lymphocytes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Serious infections associated with anticytokine therapies in the rheumatic diseases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Immunobiology of acute graft-versus-host disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Infliximab for steroid‐refractory acute GVHD: A case series

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361693

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

4 December 2018

1 reference

12 December 2020

Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation-related complications

1 reference

12 December 2020

Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies

1 reference

12 December 2020

Infliximab treatment for steroid-refractory acute graft-versus-host disease

1 reference

12 December 2020

Acute graft-versus-host disease does not require alloantigen expression on host epithelium

1 reference

12 December 2020

Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

1 reference

12 December 2020

Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses

1 reference

12 December 2020

TNF Enhances CD4+ T Cell Alloproliferation, IFN-γ Responses, and Intestinal Graft-Versus-Host Disease by IL-12-Independent Mechanisms

1 reference

12 December 2020

10.1182/BLOOD-2007-09-112987

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

1 reference